Compare, Analyse Glenmark Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
ADCOCK INGRAM
Jun-14
GLENMARK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs712311-   
Low Rs484224-   
Sales per share (Unadj.) Rs349.692.5-  
Earnings per share (Unadj.) Rs32.8-23.3-  
Cash flow per share (Unadj.) Rs44.3-19.3-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.672.6-  
Shares outstanding (eoy) m282.17168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.9 59.1%   
Avg P/E ratio x18.2-11.5 -158.8%  
P/CF ratio (eoy) x13.5-13.9 -97.3%  
Price / Book Value ratio x3.03.7 81.6%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,62545,182 373.2%   
No. of employees `00012.04.3 280.4%   
Total wages/salary Rs m20,5612,836 725.1%   
Avg. sales/employee Rs Th8,196.03,637.5 225.3%   
Avg. wages/employee Rs Th1,708.1660.5 258.6%   
Avg. net profit/employee Rs Th768.5-916.6 -83.8%   
INCOME DATA
Net Sales Rs m98,65515,616 631.8%  
Other income Rs m2,081109 1,903.4%   
Total revenues Rs m100,73615,725 640.6%   
Gross profit Rs m15,858-2,706 -586.0%  
Depreciation Rs m3,259674 483.6%   
Interest Rs m3,346423 791.0%   
Profit before tax Rs m11,335-3,694 -306.9%   
Minority Interest Rs m0-10 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,756231 1,627.5%   
Profit after tax Rs m9,250-3,935 -235.1%  
Gross profit margin %16.1-17.3 -92.8%  
Effective tax rate %33.1-6.2 -530.4%   
Net profit margin %9.4-25.2 -37.2%  
BALANCE SHEET DATA
Current assets Rs m66,96811,437 585.5%   
Current liabilities Rs m40,2116,435 624.9%   
Net working cap to sales %27.132.0 84.7%  
Current ratio x1.71.8 93.7%  
Inventory Days Days83111 75.1%  
Debtors Days Days81124 65.5%  
Net fixed assets Rs m33,3226,667 499.8%   
Share capital Rs m28273 389.2%   
"Free" reserves Rs m55,7700-   
Net worth Rs m56,05212,257 457.3%   
Long term debt Rs m35,7384,307 829.7%   
Total assets Rs m132,88823,154 573.9%  
Interest coverage x4.4-7.7 -56.7%   
Debt to equity ratio x0.60.4 181.4%  
Sales to assets ratio x0.70.7 110.1%   
Return on assets %9.5-15.2 -62.5%  
Return on equity %16.5-32.1 -51.4%  
Return on capital %17.8-19.8 -89.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m40,1400-   
CASH FLOW
From Operations Rs m13,2421,333 993.4%  
From Investments Rs m-6,990-409 1,707.9%  
From Financial Activity Rs m-7,3873,909 -189.0%  
Net Cashflow Rs m-2,9714,833 -61.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.29 Rs / ZAR

Compare GLENMARK PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: PANACEA BIOTECH  J.B.CHEMICALS  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  STERLING BIOTECH  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio (Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock (Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

How to Buy Gold and Silver (Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2020
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

GLENMARK PHARMA SHARE PRICE


Aug 7, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

FEATURED VIDEOS

Can You Win a Stock Market Championship Using My Penny Stock Strategy? Let's Find Out

How to Use Price Action to Find High Conviction Trading Ideas

Why This Attractive 'Silver' Stock With 9% Dividends Is Not a Buy

A Zero Loss Strategy that Also Maximizes Returns in Volatile Stock Markets

More Featured Videos

MARKET STATS